A Colorado government advisory board is recommending that the state expand its novel regulated psychedelics market by providing access to ibogaine in addition to psilocybin and psilocin, which are currently allowed.
At a meeting of the Natural Medicine Program Advisory Board on Thursday, members discussed the future of Colorado’s psychedelics program, which launched after voters approved a legalization initiative at the ballot. In a 5-2 vote, with two abstentions, the panel agreed to recommend therapeutic access to ibogaine.
The program already permits the clinical use of the components of so-called “magic mushrooms,” and Colorado state law also allows adults to possess and cultivate for personal use a wider range of psychedelics. But now the board is moving to add ibogaine as a substance that could be administered to adults at licensed healing centers.
“There is a lot of work to be done by the board and both agencies [that administer the program] if the plan is to implement ibogaine as one of the approved natural medicines in the regulated market,” Colorado Assistant Attorney General Ashley Moller said at the meeting.
She also stressed that, if the board is moving forward with the ibogaine recommendation to the Department of Regulatory Agencies
Read full article on Marijuana Moment
